The world's largest CROs are reaping the benefits of two major market trends: Big Pharma is finally getting back to spending big on R&D after some lean years post-downturn, and biotech is enjoying a protracted bit of bullishness that has lined pockets around the industry. But while things are looking good at the moment, prolonged success is hardly guaranteed, according to Moody's analyst Jessica Gladstone. As Ed Silverman writes in Pharmalot, Gladstone cautions that biotech funding is always fickle, and while Big Pharma is looking healthier these days, the growing popularity of megadeals could whittle down the number of large drugmakers, potentially squeezing out certain contractors. More